ArticleBriefings in functional genomics2025
Unmeasured human transcription factor ChIP-seq data shape functional genomics and demand strategic prioritization.
Article in Briefings in functional genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The distribution of fitness effects of new mutations in regulatory regions of thebioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Transcription factor (TF) chromatin immunoprecipitation followed by sequencing (ChIP-seq) is essential for identifying genome-wide TF-binding sites (TFBSs), and the collected datasets offer a variety of opportunities for downstream analyses such as inference of gene regulatory network and prediction for effects of single-nucleotide polymorphisms (SNPs) on TFBSs. Although TF ChIP-seq data continue to accumulate in public databases, comprehensive coverage of biologically relevant TF-sample pairs (i.e. combination of targeted TF and cell type) remains elusive. This is due to the need for TF-specific antibodies and large cell numbers, limiting feasible TF-cell type combinations. Moreover, ChIP-seq is measurable when the TF is expressed in the target cell type. Thus, defining the full space of biologically relevant TF-sample pairs-including both measured and unmeasured-is essential to assess and improve dataset comprehensiveness. Here, we investigated publicly available human TF ChIP-seq datasets and introduced the concept of unmeasured TF-sample pairs, defined as biologically relevant TF-sample combinations for which ChIP-seq experiments have not yet been performed. Notably, many expressed TFs in specific cell types remain unmeasured by ChIP-seq, affecting the coverage of regulatory regions revealed by TF ChIP-seq and genome-wide association study-SNP analyses. Furthermore, we propose practical strategies to efficiently supplement currently unmeasured data and discuss how these approaches can significantly enhance data-driven research. The database of unmeasured human TF-sample pairs is publicly accessible at https://moccs-db.shinyapps.io/Unmeasured_shiny_v1/, facilitating the systematic expansion of TF ChIP-seq datasets and thereby enhancing our comprehension of gene regulatory mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.